Degrading the Undruggable: A New Paradigm for Targeting KRAS

By | 18 June 2026
  • Mechanism of Action of a Novel KRAS G12d Targeted Protein Degrader: Setidegrasib
  • Clinical Overview: Efficacy and Safety in PDAC, NSCLC and other solid tumors
  • Future Directions